The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients:  A double-blind, randomised, sham-controlled trial revisited  with focus on the patient-reported outcomes.

Per Bech; Maria Gefke; Marianne Anita Lunde; Lise Lauritzen; Klaus Per Juul Martiny

doi:10.1155/2011/806298

The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes.

Per Bech, Maria Gefke, Marianne Anita Lunde, Lise Lauritzen, Klaus Per Juul Martiny

11 Citationer (Scopus)

Abstract

Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which effect size is used when comparing wanted versus unwanted clinical effects and quality of life as outcomes. In this analysis, we have especially focused on the self-reported HAM-D Methods. The antidepressive medication which the patients were resistant to was kept unchanged during the five weeks of active versus sham T-PEMF. Results. In total 21, patients received active T-PEMF, and 19 patients received sham T-PEMF. The effect size was 1.02 and 0.90, respectively, on HAM-Dand HAM-DS. Concerning side effects, the active T-PEMF reduced the baseline score on concentration problems with an effect size of 0.44 while inducing more autonomic symptoms than sham T-PEMF with an effect size of -0.41. The advantage of active over sham T-PEMF obtained an effect size of 0.48. Conclusion. Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically significant effect size level above 0.40.

Originalsprog	Engelsk
Tidsskrift	Depression Research and Treatment
Antal sider	6
DOI	https://doi.org/10.1155/2011/806298
Status	Udgivet - 4 dec. 2011

Adgang til dokumentet

10.1155/2011/806298

Fingeraftryk

Dyk ned i forskningsemnerne om 'The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes.'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Bech, P., Gefke, M., Lunde, M. A., Lauritzen, L., & Martiny, K. P. J. (2011). The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes. Depression Research and Treatment. https://doi.org/10.1155/2011/806298

The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes. / Bech, Per; Gefke, Maria; Lunde, Marianne Anita et al.

I: Depression Research and Treatment, 04.12.2011.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Bech, P, Gefke, M, Lunde, MA, Lauritzen, L & Martiny, KPJ 2011, 'The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes.', Depression Research and Treatment. https://doi.org/10.1155/2011/806298

Bech P, Gefke M, Lunde MA, Lauritzen L, Martiny KPJ. The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes. Depression Research and Treatment. 2011 dec. 4. doi: 10.1155/2011/806298

@article{caec90882ffe4e408ea3c04f7aa9e5ca,

title = "The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes.",

abstract = "Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which effect size is used when comparing wanted versus unwanted clinical effects and quality of life as outcomes. In this analysis, we have especially focused on the self-reported HAM-D Methods. The antidepressive medication which the patients were resistant to was kept unchanged during the five weeks of active versus sham T-PEMF. Results. In total 21, patients received active T-PEMF, and 19 patients received sham T-PEMF. The effect size was 1.02 and 0.90, respectively, on HAM-Dand HAM-DS. Concerning side effects, the active T-PEMF reduced the baseline score on concentration problems with an effect size of 0.44 while inducing more autonomic symptoms than sham T-PEMF with an effect size of -0.41. The advantage of active over sham T-PEMF obtained an effect size of 0.48. Conclusion. Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically significant effect size level above 0.40.",

author = "Per Bech and Maria Gefke and Lunde, {Marianne Anita} and Lise Lauritzen and Martiny, {Klaus Per Juul}",

year = "2011",

month = dec,

day = "4",

doi = "10.1155/2011/806298",

language = "English",

journal = "Depression Research and Treatment",

issn = "2090-1321",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - The pharmacopsychometric triangle to illustrate the effectiveness of T-PEMF concomitant with antidepressants in treatment resistant patients: A double-blind, randomised, sham-controlled trial revisited with focus on the patient-reported outcomes.

AU - Bech, Per

AU - Gefke, Maria

AU - Lunde, Marianne Anita

AU - Lauritzen, Lise

AU - Martiny, Klaus Per Juul

PY - 2011/12/4

Y1 - 2011/12/4

N2 - Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which effect size is used when comparing wanted versus unwanted clinical effects and quality of life as outcomes. In this analysis, we have especially focused on the self-reported HAM-D Methods. The antidepressive medication which the patients were resistant to was kept unchanged during the five weeks of active versus sham T-PEMF. Results. In total 21, patients received active T-PEMF, and 19 patients received sham T-PEMF. The effect size was 1.02 and 0.90, respectively, on HAM-Dand HAM-DS. Concerning side effects, the active T-PEMF reduced the baseline score on concentration problems with an effect size of 0.44 while inducing more autonomic symptoms than sham T-PEMF with an effect size of -0.41. The advantage of active over sham T-PEMF obtained an effect size of 0.48. Conclusion. Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically significant effect size level above 0.40.

AB - Background. Our T-PEMF trial has been revisited with focus on the pharmacopsychometric triangle in which effect size is used when comparing wanted versus unwanted clinical effects and quality of life as outcomes. In this analysis, we have especially focused on the self-reported HAM-D Methods. The antidepressive medication which the patients were resistant to was kept unchanged during the five weeks of active versus sham T-PEMF. Results. In total 21, patients received active T-PEMF, and 19 patients received sham T-PEMF. The effect size was 1.02 and 0.90, respectively, on HAM-Dand HAM-DS. Concerning side effects, the active T-PEMF reduced the baseline score on concentration problems with an effect size of 0.44 while inducing more autonomic symptoms than sham T-PEMF with an effect size of -0.41. The advantage of active over sham T-PEMF obtained an effect size of 0.48. Conclusion. Active T-PEMF was found superior to sham T-PEMF within the pharmacopsychometric triangle with a clinically significant effect size level above 0.40.

U2 - 10.1155/2011/806298

DO - 10.1155/2011/806298

M3 - Journal article

C2 - 21738869

SN - 2090-1321

JO - Depression Research and Treatment

JF - Depression Research and Treatment

ER -